[Pass] Universal Vision Biotechnology Co., Ltd. (3218 TT)
Last week, you highlighted a potential opportunity in UVB. What’s your suggestion?
Pass.
Questionable capital allocation:
Loss-making in China. After nearly 10 years, UVB’s subsidiary in China still has not broken even. Despite that, the company is investing more in China.
Speculating in TSMC. UVB spent more than one year’s operating profits on shares in TSMC (2330 TT).
Liquidity?
17 Nov 2026
Share price: TWD 123.00
Market capitalisation: TWD 10,548 mn (USD 320 mn)
Enterprise value (EV): TWD 10,896 mn (USD 330 mn)
Average daily volume (ADV): TWD 22 mn (USD 1 mn)
NTM P/E: 9x
What does UVB do?
UVB provides vision care services in Taiwan and China through partner clinics.
It is the largest player, with ~ 50% market share in the refractive surgery market. The market share trend is stable.
The details are not important, since UVB is an obvious pass. If you’re curious, check out my previous post.
Questionable capital allocation
Why do you say UVB is an obvious pass?
In 2017, UVB established a subsidiary in China (Taixue). It’s almost 10 years, but Taixue still has not broken even:

Taixue losses for Q3’26: TWD 11 mn. YTD losses: TWD 26 mn.
Source: UVB (2026)
Although the losses were immaterial, they strongly suggests UVB lacks competitive advantage in China. This is a competitive market dominated by the likes of Aier Eye Hospital Group Co., Ltd. (300015 CH).
Despite the lack of a competitive advantage, UVB is ploughing more cash into China. In January 2026, it opened a new hospital in Jiangsu. Expansions are underway and scheduled for completion in 2027.
That doesn’t sound like a good use of shareholders' cash. Return on incremental capital seems poor.
Next point. Why is UVB investing in TSMC?


